Méhtestrák: vizsgálatok itt: Dél-Korea
35 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Where
- Changwon, Daegu, Goyang, Seongnam, Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06340568 · EU 2023-507525-42-00 - 3. fázisTaking peopleA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Where
- Daegu, Gyeonggi-do, Seoul
- Életkor
- 18 év and over
- People
- 1123 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06952504 · EU 2024-519331-42-00 - 3. fázisTaking peopleImpact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- Where
- Incheon, Seoul
- Életkor
- 18 év and over
- People
- 428 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT05646316 - 1. fázisTaking peopleA Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Where
- Gwangmyeong, Seoul
- Életkor
- 19 év and over
- People
- 238 worldwide
- Run by
- NiKang Therapeutics, Inc.
See details and how to joinNCT06586957 - 1/2. fázisTaking peopleRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 952 worldwide
- Run by
- Genmab
See details and how to joinNCT05579366 - 1. fázisTaking peopleA Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Goyang-si Gyeonggi-do
- Életkor
- 18 év and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00 - 2. fázisTaking peopleA Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Where
- Gangnam-Gu, Guro-gu, Hwasun-Eup, Jongno-gu, Seodaemun-gu, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00 - 2. fázisTaking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Jongno -Gu, Seoul
- Életkor
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - 3. fázisTaking peopleA Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
- Where
- Cheongju Chungcheongbuk-do, Daegu, Seongnam-si Gyeonggi-do, Seoul
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07286331 · EU 2025-523362-25-00 - 3. fázisTaking peopleA Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
- Where
- Daegu
- Életkor
- 18 év and over
- People
- 610 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07684599 · EU 2025-523363-37-00 - 1/2. fázisTaking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Busan, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - 3. fázisTaking peopleA Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
- Where
- Daegu, Seoul
- Életkor
- 18 év and over
- People
- 710 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07022483 · EU 2024-519444-33-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Daegu, Gyeonggi-do, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 3. fázisTaking peopleDESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Where
- Goyang-si, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06989112 · EU 2023-508056-19-00 - No phaseTaking peopleProactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 1000
- Run by
- Seoul National University Hospital
See details and how to joinNCT06977594 - 1/2. fázisTaking peopleStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Seoul
- Életkor
- 18 év to 130 év
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - 1/2. fázisTaking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Seoul
- Életkor
- 18 év to 130 év
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 1/2. fázisTaking peopleStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 890 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Seoul
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - No phaseTaking peopleDurvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
- Where
- Seoul
- People
- 50
- Run by
- AstraZeneca
See details and how to joinNCT06995833 - 1/2. fázisTaking peopleA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Where
- Gyeonggi-do, Seoul
- Életkor
- 18 év and over
- People
- 796 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05150691 - 1/2. fázisTaking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Daegu, Goyang-si, Incheon, Seoul
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - 3. fázisTaking peoplePuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Where
- Goyang-si, Gwangjin-gu, Seoul, Songpa-gu, Suwon
- Életkor
- 18 év and over
- People
- 800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07044336 · EU 2024-518777-34-00